AI in drug discovery and development: Will it live up to the hype?
The recent explosion of generative artificial intelligence (AI) has fueled interest in and concern over the use of AI in drug discovery and research and...
Matthew Featherstone is a vice president in the Life Sciences Practice of CRA, based in the London office.
Mr. Featherstone has more than 15 years of experience helping clients in the Life Sciences space with opportunity assessments, commercial due diligence, commercialization strategy, and launch and brand planning. He advises on assessing commercial potential for pharma and digital health products, as well as go to market approaches for the US, Europe, and emerging markets.
Mr. Featherstone is currently based in London after four years on the West Coast, where he specialized in supporting small and emerging pharma and biotech companies with their strategic development and commercialization efforts.
He focuses on evaluating potential and corporate strategies in the digital health space. He also has a passion for supporting his clients in understanding and improving the patient journey through patient support and patient engagement programs.